New drug tested in people with liver disease

NCT ID NCT06957756

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study looked at how the body handles a drug called BI 1584862 in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, plus a group with healthy livers, took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to understand how liver impairment affects the drug's processing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1584862
What this could lead to: If successful, this study could help doctors understand how to safely dose BI 1584862 in people with liver problems.
What could go wrong: This is an early phase 1 study with only 43 participants, so results may not apply to everyone. The drug's effectiveness is not being tested here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY

Contacts and locations

Show contact details

Locations

American Research Corporation

San Antonio, Texas, 78215, United States
Arizona Clinical Trials - Chandler

Chandler, Arizona, 85225, United States
Omega Research Orlando, LLC

Orlando, Florida, 32808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.